Biofilm formation in food industries: Challenges and control strategies for food safety

Various pathogens have the ability to grow on food matrices and instruments. This grow may reach to form biofilms. Bacterial biofilms are community of microorganisms embedded in extracellular polymeric substances (EPSs) containing lipids, DNA, proteins, and polysaccharides. These EPSs provide a tolerance and favorable living condition for microorganisms. Biofilm formations could not only contribute a risk for food safety but also have negative impacts on healthcare sector. Once biofilms form, they reveal resistances to traditional detergents and disinfectants, leading to cross-contamination. Inhibition of biofilms formation and abolition of mature biofilms is the main target for controlling of biofilm hazards in the food industry. Some novel eco-friendly technologies such as ultrasound, ultraviolet, cold plasma, magnetic nanoparticles, different chemicals additives as vitamins, D-amino acids, enzymes, antimicrobial peptides, and many other inhibitors provide a significant value on biofilm inhibition. These anti-biofilm agents represent promising tools for food industries and researchers to interfere with different phases of biofilms including adherence, quorum sensing molecules, and cell-to-cell communication. This perspective review highlights the biofilm formation mechanisms, issues associated with biofilms, environmental factors influencing bacterial biofilm development, and recent strategies employed to control biofilm-forming bacteria in the food industry. Further studies are still needed to explore the effects of biofilm regulation in food industries and exploit more regulation strategies for improving the quality and decreasing economic losses.

Antibacterial Activity of Metallic Nanoparticles against Multidrug-Resistant Pathogens Isolated from Environmental Samples: Nanoparticles/Antibiotic Combination Therapy and Cytotoxicity Study

Multidrug-resistant organisms have increased the prevalence of infectious diseases and have become the leading source of death globally. The adverse effects associated with conventional antibiotics cannot be underestimated, and as a result, the quest for antibacterial agents has received great attention over the years. Therefore, the current research was designed to synthesize and examine the antibacterial properties of two metallic nanoparticles, silver nanoparticles (AgNPs) and zinc oxide nanoparticles (ZnONPs), as well as their antibiotic combination therapy against multidrug-resistant bacteria. AgNPs and ZnONPs were synthesized by the coprecipitation method and characterized. Thereafter, their antibacterial activity against multidrug-resistant bacteria was investigated using the microdilution technique. Subsequently, the interactions between the synthesized nanoparticles and antibiotics were evaluated by checkerboard assay. Time-kill assays were carried out to assess bacteriostatic or bactericidal effects, and the cytotoxicity study was carried out by MTT assay. The SEM analysis of AgNPs and ZnONPs were spherical with an average size of 21.03 and 43.37 nm, respectively. FTIR analysis showed the characteristics of the metal-oxygen vibrational band for both materials around 450 cm-1, which indicated the successful synthesis of these antibacterial agents. The EDX characterization revealed Zn and O with 77.89% and 18.24% abundance in ZnONPs and Ag with 95.65% abundance in AgNPs. UV-vis absorption spectra of AgNPs was obtained around 400 nm. ZnONPs showed a moderate antibacterial effect against Enterococcus species with a MIC range of 2.5-5 mg/mL, while AgNPs demonstrated a strong antibacterial effect against the tested bacterial strains with a MIC range of 0.078-0.039 mg/mL. The ZnONPs were found to be cytotoxic against Vero cell lines at the tested concentrations, whereas AgNPs had no cytotoxic effect at lower concentrations. Their combination activities showed synergetic and additive effects. These findings revealed that these synthesized materials could serve as alternate antibacterial agents against multidrug-resistant Acinetobacter baumanni and Enterococcus species.

Combination of Silver Nanoparticles and Vancomycin to Overcome Antibiotic Resistance in Planktonic/Biofilm Cell from Clinical and Animal Source

This study aims to evaluate the prevalence of multidrug-resistant (MDR) and biofilm-forming pathogens from animal source compared to clinical ones. In addition, to assess the antibacterial and antibiofilm activity of silver nanoparticles (AgNPs) alone and/or mixed with vancomycin. Out of 62 bacterial isolates from animal respiratory tract infection (RTI), 50.00% were defined as MDR, while among human ones, 44.00% were MDR. The bacteria Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus pneumoniae were the predominant isolated bacteria from both animal and human origin with frequency percentage of 50.00, 22.32, and 18.75, respectively. Among Staph. aureus strains, mecA gene was detected in 60.00% and 61.54% of animal and human isolates, respectively, while mec_ALGA251 (mecC) gene was detected in 13.33% and 15.38% of animal and human isolates, respectively. Biofilm formation ability among animal isolates was 83.87%, while among human ones was 86.00%. AgNPs were effective in inhibiting planktonic cells with minimal inhibitory concentration (MIC) values (0.625-10 μg/mL), as well as eradicating biofilm with minimal biofilm eradication concentration values (1.25-10 μg/mL). Noticeable low MIC of AgNPs was required for the isolates from animal source (0.625-5 μg/mL) compared to clinical ones (0.625-10 μg/mL). Remarkable reduction in AgNP effective concentration was observed after combination with 1/4 MIC of vancomycin with minimum recorded concentration of 0.08 μg/mL. In conclusion, the prevalence of MDR among RT pathogens was recorded with high ability to produce biofilm and virulence factors from both animal and human pathogens. AgNPs showed strong antibacterial and antibiofilm activity alone and mixed with vancomycin, with up to fourfold reduction of AgNP inhibitory dose.